{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Alzheimer\u2019s disease", "induced pluripotent stem cells", "\u03b3-Secretase"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "32079110", "DateCompleted": {"Year": "2020", "Month": "11", "Day": "20"}, "DateRevised": {"Year": "2020", "Month": "11", "Day": "20"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "02", "Day": "16"}], "Language": ["eng"], "ELocationID": ["1327", "10.3390/ijms21041327"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "21", "Issue": "4", "PubDate": {"Year": "2020", "Month": "Feb", "Day": "16"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Human-Induced Pluripotent Stem Cells and Herbal Small-Molecule Drugs for Treatment of Alzheimer's Disease.", "Abstract": {"AbstractText": ["Alzheimer's disease (AD) is characterized by extracellular amyloid plaques composed of the \u03b2-amyloid peptides and intracellular neurofibrillary tangles and associates with progressive declines in memory and cognition. Several genes play important roles and regulate enzymes that produce a pathological accumulation of \u03b2-amyloid in the brain, such as gamma secretase (\u03b3-secretase). Induced pluripotent stem cells from patients with Alzheimer's disease with different underlying genetic mechanisms may help model different phenotypes of Alzheimer's disease and facilitate personalized drug screening platforms for the identification of small molecules. We also discuss recent developments by \u03b3-secretase inhibitors and modulators in the treatment of AD. In addition, small-molecule drugs isolated from Chinese herbal medicines have been shown effective in treating Alzheimer's disease. We propose a mechanism of small-molecule drugs in treating Alzheimer's disease. Combining therapy with different small-molecule drugs may increase the chance of symptomatic treatment. A customized strategy tailored to individuals and in combination with therapy may be a more suitable treatment option for Alzheimer's disease in the future."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Bioinnovation Center, Buddhist Tzu Chi Medical foundation, Hualien 97002, Taiwan."}, {"Identifier": [], "Affiliation": "Department of Life Science, National Dong Hwa University, Hualien 97401, Taiwan."}], "LastName": "Wuli", "ForeName": "Wei", "Initials": "W"}, {"Identifier": ["0000-0001-6611-9440"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Neurosurgery, Hualien Tzu Chi General Hospital, Hualien 97002, Taiwan."}], "LastName": "Tsai", "ForeName": "Sheng-Tzung", "Initials": "ST"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Life Science, National Dong Hwa University, Hualien 97401, Taiwan."}], "LastName": "Chiou", "ForeName": "Tzyy-Wen", "Initials": "TW"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Bioinnovation Center, Buddhist Tzu Chi Medical foundation, Hualien 97002, Taiwan."}, {"Identifier": [], "Affiliation": "Department of Pathology, Hualien Tzu Chi General Hospital, Hualien 97002, Taiwan."}], "LastName": "Harn", "ForeName": "Horng-Jyh", "Initials": "HJ"}], "GrantList": [{"GrantID": "TCMF-SP 108-03(108)", "Agency": "Buddhist Tzu Chi Medical Foundation", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Amyloid"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "0", "NameOfSubstance": "Small Molecule Libraries"}, {"RegistryNumber": "EC 3.4.-", "NameOfSubstance": "Amyloid Precursor Protein Secretases"}], "MeshHeadingList": [{"QualifierName": ["drug therapy", "genetics", "metabolism", "pathology"], "DescriptorName": "Alzheimer Disease"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Amyloid"}, {"QualifierName": ["antagonists & inhibitors", "genetics", "metabolism"], "DescriptorName": "Amyloid Precursor Protein Secretases"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["methods"], "DescriptorName": "Drug Discovery"}, {"QualifierName": ["methods"], "DescriptorName": "Drug Evaluation, Preclinical"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug effects", "metabolism", "pathology"], "DescriptorName": "Induced Pluripotent Stem Cells"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Plant Extracts"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Small Molecule Libraries"}], "CoiStatement": "The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Van der Flier W.M., Scheltens P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. J. Alzheimers Dis. 2018;62:1091\u20131111. doi: 10.3233/JAD-170850.", "ArticleIdList": ["10.3233/JAD-170850", "PMC5870023", "29562540"]}, {"Citation": "Association A.S. 2019 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2019;15:321\u2013387. doi: 10.1016/j.jalz.2019.01.010.", "ArticleIdList": ["10.1016/j.jalz.2019.01.010"]}, {"Citation": "Forstl H., Kurz A. Clinical features of Alzheimer\u2019s disease. Eur. Arch. Psychiatry Clin. Neurosci. 1999;249:288\u2013290. doi: 10.1007/s004060050101.", "ArticleIdList": ["10.1007/s004060050101", "10653284"]}, {"Citation": "Mahalingam S., Chen M.K. Neuroimaging in Dementias. Semin Neurol. 2019;39:188\u2013199. doi: 10.1055/s-0039-1678580.", "ArticleIdList": ["10.1055/s-0039-1678580", "30925612"]}, {"Citation": "Koedam E.L., Lauffer V., van der Vlies A.E., van der Flier W.M., Scheltens P., Pijnenburg Y.A. Early-versus late-onset Alzheimer\u2019s disease: more than age alone. J. Alzheimers Dis. 2010;19:1401\u20131408. doi: 10.3233/JAD-2010-1337.", "ArticleIdList": ["10.3233/JAD-2010-1337", "20061618"]}, {"Citation": "Mendez M.F. Early-onset Alzheimer\u2019s disease: Nonamnestic subtypes and type 2 AD. Arch. Med. Res. 2012;43:677\u2013685. doi: 10.1016/j.arcmed.2012.11.009.", "ArticleIdList": ["10.1016/j.arcmed.2012.11.009", "PMC3532551", "23178565"]}, {"Citation": "Duce J.A., Tsatsanis A., Cater M.A., James S.A., Robb E., Wikhe K., Leong S.L., Perez K., Johanssen T., Greenough M.A., et al. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer\u2019s disease. Cell. 2010;142:857\u2013867. doi: 10.1016/j.cell.2010.08.014.", "ArticleIdList": ["10.1016/j.cell.2010.08.014", "PMC2943017", "20817278"]}, {"Citation": "De Strooper B. Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007;8:141\u2013146. doi: 10.1038/sj.embor.7400897.", "ArticleIdList": ["10.1038/sj.embor.7400897", "PMC1796779", "17268505"]}, {"Citation": "Bekris L.M., Yu C.E., Bird T.D., Tsuang D.W. Genetics of Alzheimer disease. J. Geriatr Psychiatry Neurol. 2010;23:213\u2013227. doi: 10.1177/0891988710383571.", "ArticleIdList": ["10.1177/0891988710383571", "PMC3044597", "21045163"]}, {"Citation": "Chow V.W., Mattson M.P., Wong P.C., Gleichmann M. An overview of APP processing enzymes and products. Neuromolecular Med. 2010;12:1\u201312. doi: 10.1007/s12017-009-8104-z.", "ArticleIdList": ["10.1007/s12017-009-8104-z", "PMC2889200", "20232515"]}, {"Citation": "Bloom G.S. Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71:505\u2013508. doi: 10.1001/jamaneurol.2013.5847.", "ArticleIdList": ["10.1001/jamaneurol.2013.5847", "24493463"]}, {"Citation": "Westerink R.H., Ewing A.G. The PC12 cell as model for neurosecretion. Acta Physiol (Oxf) 2008;192:273\u2013285. doi: 10.1111/j.1748-1716.2007.01805.x.", "ArticleIdList": ["10.1111/j.1748-1716.2007.01805.x", "PMC2663028", "18005394"]}, {"Citation": "Jiang X., Kumar M., Zhu Y. Protective Effect of Hyperforin on beta Amyloid Protein Induced Apoptosis in PC12 Cells and Colchicine Induced Alzheimer\u2019s Disease: An Anti-oxidant and Anti-inflammatory Therapy. J. Oleo Sci. 2018;67:1443\u20131453. doi: 10.5650/jos.ess18117.", "ArticleIdList": ["10.5650/jos.ess18117", "30404965"]}, {"Citation": "Biedler J.L., Helson L., Spengler B.A. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res. 1973;33:2643\u20132652.", "ArticleIdList": ["4748425"]}, {"Citation": "Pascual-Caro C., Berrocal M., Lopez-Guerrero A.M., Alvarez-Barrientos A., Pozo-Guisado E., Gutierrez-Merino C., Mata A.M., Martin-Romero F.J. STIM1 deficiency is linked to Alzheimer\u2019s disease and triggers cell death in SH-SY5Y cells by upregulation of L-type voltage-operated Ca(2+) entry. J. Mol. Med. (Berl) 2018;96:1061\u20131079. doi: 10.1007/s00109-018-1677-y.", "ArticleIdList": ["10.1007/s00109-018-1677-y", "PMC6133163", "30088035"]}, {"Citation": "Ng J., Kaur H., Collier T., Chang K., Brooks A.E.S., Allison J.R., Brimble M.A., Hickey A., Birch N.P. Site-specific glycation of Abeta1-42 affects fibril formation and is neurotoxic. J. Biol. Chem. 2019;294:8806\u20138818. doi: 10.1074/jbc.RA118.006846.", "ArticleIdList": ["10.1074/jbc.RA118.006846", "PMC6552435", "30996005"]}, {"Citation": "Galante D., Corsaro A., Florio T., Vella S., Pagano A., Sbrana F., Vassalli M., Perico A., D\u2019Arrigo C. Differential toxicity, conformation and morphology of typical initial aggregation states of Abeta1-42 and Abetapy3-42 beta-amyloids. Int. J. Biochem. Cell Biol. 2012;44:2085\u20132093. doi: 10.1016/j.biocel.2012.08.010.", "ArticleIdList": ["10.1016/j.biocel.2012.08.010", "22903022"]}, {"Citation": "Arber C., Lovejoy C., Wray S. Stem cell models of Alzheimer\u2019s disease: Progress and challenges. Alzheimers Res. Ther. 2017;9:42. doi: 10.1186/s13195-017-0268-4.", "ArticleIdList": ["10.1186/s13195-017-0268-4", "PMC5470327", "28610595"]}, {"Citation": "Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663\u2013676. doi: 10.1016/j.cell.2006.07.024.", "ArticleIdList": ["10.1016/j.cell.2006.07.024", "16904174"]}, {"Citation": "Shimojo D., Onodera K., Doi-Torii Y., Ishihara Y., Hattori C., Miwa Y., Tanaka S., Okada R., Ohyama M., Shoji M., et al. Rapid, efficient, and simple motor neuron differentiation from human pluripotent stem cells. Mol. Brain. 2015;8:79. doi: 10.1186/s13041-015-0172-4.", "ArticleIdList": ["10.1186/s13041-015-0172-4", "PMC4666063", "26626025"]}, {"Citation": "Kikuchi T., Morizane A., Doi D., Magotani H., Onoe H., Hayashi T., Mizuma H., Takara S., Takahashi R., Inoue H., et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson\u2019s disease model. Nature. 2017;548:592\u2013596. doi: 10.1038/nature23664.", "ArticleIdList": ["10.1038/nature23664", "28858313"]}, {"Citation": "Watson L.M., Wong M.M.K., Vowles J., Cowley S.A., Becker E.B.E. A Simplified Method for Generating Purkinje Cells from Human-Induced Pluripotent Stem Cells. Cerebellum. 2018;17:419\u2013427. doi: 10.1007/s12311-017-0913-2.", "ArticleIdList": ["10.1007/s12311-017-0913-2", "PMC6028833", "29397531"]}, {"Citation": "Crompton L.A., Byrne M.L., Taylor H., Kerrigan T.L., Bru-Mercier G., Badger J.L., Barbuti P.A., Jo J., Tyler S.J., Allen S.J., et al. Stepwise, non-adherent differentiation of human pluripotent stem cells to generate basal forebrain cholinergic neurons via hedgehog signaling. Stem Cell Res. 2013;11:1206\u20131221. doi: 10.1016/j.scr.2013.08.002.", "ArticleIdList": ["10.1016/j.scr.2013.08.002", "24013066"]}, {"Citation": "Muratore C.R., Srikanth P., Callahan D.G., Young-Pearse T.L. Comparison and optimization of hiPSC forebrain cortical differentiation protocols. PLoS ONE. 2014;9:e105807. doi: 10.1371/journal.pone.0105807.", "ArticleIdList": ["10.1371/journal.pone.0105807", "PMC4148335", "25165848"]}, {"Citation": "Stanslowsky N., Haase A., Martin U., Naujock M., Leffler A., Dengler R., Wegner F. Functional differentiation of midbrain neurons from human cord blood-derived induced pluripotent stem cells. Stem Cell Res. Ther. 2014;5:35. doi: 10.1186/scrt423.", "ArticleIdList": ["10.1186/scrt423", "PMC4055096", "24636737"]}, {"Citation": "Wang S., Wang B., Pan N., Fu L., Wang C., Song G., An J., Liu Z., Zhu W., Guan Y., et al. Differentiation of human induced pluripotent stem cells to mature functional Purkinje neurons. Sci. Rep. 2015;5:9232. doi: 10.1038/srep09232.", "ArticleIdList": ["10.1038/srep09232", "PMC4363833", "25782665"]}, {"Citation": "Callahan P.M., Bertrand D., Bertrand S., Plagenhoef M.R., Terry A.V., Jr. Tropisetron sensitizes alpha7 containing nicotinic receptors to low levels of acetylcholine in vitro and improves memory-related task performance in young and aged animals. Neuropharmacology. 2017;117:422\u2013433. doi: 10.1016/j.neuropharm.2017.02.025.", "ArticleIdList": ["10.1016/j.neuropharm.2017.02.025", "28259598"]}, {"Citation": "Chien M.Y., Chuang C.H., Chern C.M., Liou K.T., Liu D.Z., Hou Y.C., Shen Y.C. Salvianolic acid A alleviates ischemic brain injury through the inhibition of inflammation and apoptosis and the promotion of neurogenesis in mice. Free Radic. Biol. Med. 2016;99:508\u2013519. doi: 10.1016/j.freeradbiomed.2016.09.006.", "ArticleIdList": ["10.1016/j.freeradbiomed.2016.09.006", "27609227"]}, {"Citation": "Fujiwara N., Shimizu J., Takai K., Arimitsu N., Saito A., Kono T., Umehara T., Ueda Y., Wakisaka S., Suzuki T., et al. Restoration of spatial memory dysfunction of human APP transgenic mice by transplantation of neuronal precursors derived from human iPS cells. Pt BNeurosci Lett. 2013;557:129\u2013134. doi: 10.1016/j.neulet.2013.10.043.", "ArticleIdList": ["10.1016/j.neulet.2013.10.043", "24466594"]}, {"Citation": "Tang T., Xiao J., Suh C.Y., Burroughs A., Cerminara N.L., Jia L., Marshall S.P., Wise A.K., Apps R., Sugihara I., et al. Heterogeneity of Purkinje cell simple spike-complex spike interactions: zebrin- and non-zebrin-related variations. J. Physiol. 2017;595:5341\u20135357. doi: 10.1113/JP274252.", "ArticleIdList": ["10.1113/JP274252", "PMC5538194", "28516455"]}, {"Citation": "Mavroudis I.A., Manani M.G., Petrides F., Petsoglou K., Njau S.D., Costa V.G., Baloyannis S.J. Dendritic and spinal pathology of the Purkinje cells from the human cerebellar vermis in Alzheimer\u2019s disease. Psychiatr Danub. 2013;25:221\u2013226.", "ArticleIdList": ["24048388"]}, {"Citation": "Jiang Y.Q., Wang X.L., Cao X.H., Ye Z.Y., Li L., Cai W.Q. Increased heat shock transcription factor 1 in the cerebellum reverses the deficiency of Purkinje cells in Alzheimer\u2019s disease. Brain Res. 2013;1519:105\u2013111. doi: 10.1016/j.brainres.2013.04.059.", "ArticleIdList": ["10.1016/j.brainres.2013.04.059", "23665061"]}, {"Citation": "Tcw J. Human iPSC application in Alzheimer\u2019s disease and Tau-related neurodegenerative diseases. Neurosci Lett. 2019;699:31\u201340. doi: 10.1016/j.neulet.2019.01.043.", "ArticleIdList": ["10.1016/j.neulet.2019.01.043", "30685408"]}, {"Citation": "Mungenast A.E., Siegert S., Tsai L.H. Modeling Alzheimer\u2019s disease with human induced pluripotent stem (iPS) cells. Mol. Cell Neurosci. 2016;73:13\u201331. doi: 10.1016/j.mcn.2015.11.010.", "ArticleIdList": ["10.1016/j.mcn.2015.11.010", "PMC5930170", "26657644"]}, {"Citation": "Kondo T., Imamura K., Funayama M., Tsukita K., Miyake M., Ohta A., Woltjen K., Nakagawa M., Asada T., Arai T., et al. iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid beta Combination for Alzheimer\u2019s Disease. Cell Rep. 2017;21:2304\u20132312. doi: 10.1016/j.celrep.2017.10.109.", "ArticleIdList": ["10.1016/j.celrep.2017.10.109", "29166618"]}, {"Citation": "Oksanen M., Hyotylainen I., Voutilainen J., Puttonen K.A., Hamalainen R.H., Graff C., Lehtonen S., Koistinaho J. Generation of a human induced pluripotent stem cell line (LL008 1.4) from a familial Alzheimer\u2019s disease patient carrying a double KM670/671NL (Swedish) mutation in APP gene. Stem Cell Res. 2018;31:181\u2013185. doi: 10.1016/j.scr.2018.07.024.", "ArticleIdList": ["10.1016/j.scr.2018.07.024", "30099334"]}, {"Citation": "Israel M.A., Yuan S.H., Bardy C., Reyna S.M., Mu Y., Herrera C., Hefferan M.P., Van Gorp S., Nazor K.L., Boscolo F.S., et al. Probing sporadic and familial Alzheimer\u2019s disease using induced pluripotent stem cells. Nature. 2012;482:216\u2013220. doi: 10.1038/nature10821.", "ArticleIdList": ["10.1038/nature10821", "PMC3338985", "22278060"]}, {"Citation": "Lehtonen S., Hoytylainen I., Voutilainen J., Sonninen T.M., Kuusisto J., Laakso M., Hamalainen R.H., Oksanen M., Koistinaho J. Generation of a human induced pluripotent stem cell line from a patient with a rare A673T variant in amyloid precursor protein gene that reduces the risk for Alzheimer\u2019s disease. Stem Cell Res. 2018;30:96\u201399. doi: 10.1016/j.scr.2018.05.014.", "ArticleIdList": ["10.1016/j.scr.2018.05.014", "29807259"]}, {"Citation": "Potter H., Granic A., Caneus J. Role of Trisomy 21 Mosaicism in Sporadic and Familial Alzheimer\u2019s Disease. Curr. Alzheimer Res. 2016;13:7\u201317. doi: 10.2174/156720501301151207100616.", "ArticleIdList": ["10.2174/156720501301151207100616", "PMC5570437", "26651340"]}, {"Citation": "Chang C.Y., Chen S.M., Lu H.E., Lai S.M., Lai P.S., Shen P.W., Chen P.Y., Shen C.I., Harn H.J., Lin S.Z., et al. N-butylidenephthalide attenuates Alzheimer\u2019s disease-like cytopathy in Down syndrome induced pluripotent stem cell-derived neurons. Sci. Rep. 2015;5:8744. doi: 10.1038/srep08744.", "ArticleIdList": ["10.1038/srep08744", "PMC4348654", "25735452"]}, {"Citation": "Yagi T., Ito D., Okada Y., Akamatsu W., Nihei Y., Okano H., Suzuki N. [Modeling familial Alzheimer\u2019s disease with induced pluripotent stem cells] Rinsho Shinkeigaku. 2012;52:1134\u20131136. doi: 10.5692/clinicalneurol.52.1134.", "ArticleIdList": ["10.5692/clinicalneurol.52.1134", "23196540"]}, {"Citation": "Oksanen M., Petersen A.J., Naumenko N., Puttonen K., Lehtonen S., Gubert Olive M., Shakirzyanova A., Leskela S., Sarajarvi T., Viitanen M., et al. PSEN1 Mutant iPSC-Derived Model Reveals Severe Astrocyte Pathology in Alzheimer\u2019s Disease. Stem Cell Rep. 2017;9:1885\u20131897. doi: 10.1016/j.stemcr.2017.10.016.", "ArticleIdList": ["10.1016/j.stemcr.2017.10.016", "PMC5785689", "29153989"]}, {"Citation": "Silva M.C., Cheng C., Mair W., Almeida S., Fong H., Biswas M.H.U., Zhang Z., Huang Y., Temple S., Coppola G., et al. Human iPSC-Derived Neuronal Model of Tau-A152T Frontotemporal Dementia Reveals Tau-Mediated Mechanisms of Neuronal Vulnerability. Stem Cell Rep. 2016;7:325\u2013340. doi: 10.1016/j.stemcr.2016.08.001.", "ArticleIdList": ["10.1016/j.stemcr.2016.08.001", "PMC5032560", "27594585"]}, {"Citation": "Garcia-Leon J.A., Cabrera-Socorro A., Eggermont K., Swijsen A., Terryn J., Fazal R., Nami F., Ordovas L., Quiles A., Lluis F., et al. Generation of a human induced pluripotent stem cell-based model for tauopathies combining three microtubule-associated protein TAU mutations which displays several phenotypes linked to neurodegeneration. Alzheimers Dement. 2018;14:1261\u20131280. doi: 10.1016/j.jalz.2018.05.007.", "ArticleIdList": ["10.1016/j.jalz.2018.05.007", "30036493"]}, {"Citation": "Iovino M., Agathou S., Gonzalez-Rueda A., Del Castillo Velasco-Herrera M., Borroni B., Alberici A., Lynch T., O\u2019Dowd S., Geti I., Gaffney D., et al. Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with MAPT mutations. Brain. 2015;138:3345\u20133359. doi: 10.1093/brain/awv222.", "ArticleIdList": ["10.1093/brain/awv222", "PMC4620511", "26220942"]}, {"Citation": "Maclean G.A., Menne T.F., Guo G., Sanchez D.J., Park I.H., Daley G.Q., Orkin S.H. Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc. Natl. Acad. Sci. USA. 2012;109:17567\u201317572. doi: 10.1073/pnas.1215468109.", "ArticleIdList": ["10.1073/pnas.1215468109", "PMC3491455", "23045682"]}, {"Citation": "Clarimon J., Djaldetti R., Lleo A., Guerreiro R.J., Molinuevo J.L., Paisan-Ruiz C., Gomez-Isla T., Blesa R., Singleton A., Hardy J. Whole genome analysis in a consanguineous family with early onset Alzheimer\u2019s disease. Neurobiol. Aging. 2009;30:1986\u20131991. doi: 10.1016/j.neurobiolaging.2008.02.008.", "ArticleIdList": ["10.1016/j.neurobiolaging.2008.02.008", "18387709"]}, {"Citation": "Awada A.A. Early and late-onset Alzheimer\u2019s disease: What are the differences? J. Neurosci. Rural Pract. 2015;6:455\u2013456. doi: 10.4103/0976-3147.154581.", "ArticleIdList": ["10.4103/0976-3147.154581", "PMC4481819", "26167048"]}, {"Citation": "Kehoe P., Williams J., Lovestone S., Wilcock G., Owen M.J. Presenilin-1 polymorphism and Alzheimer\u2019s disease. The UK Alzheimer\u2019s Disease Collaborative Group. Lancet. 1996;347:1185. doi: 10.1016/S0140-6736(96)90643-1.", "ArticleIdList": ["10.1016/S0140-6736(96)90643-1", "8609781"]}, {"Citation": "Haapasalo A., Kovacs D.M. The many substrates of presenilin/gamma-secretase. J. Alzheimers Dis. 2011;25:3\u201328. doi: 10.3233/JAD-2011-101065.", "ArticleIdList": ["10.3233/JAD-2011-101065", "PMC3281584", "21335653"]}, {"Citation": "Yang G., Zhou R., Zhou Q., Guo X., Yan C., Ke M., Lei J., Shi Y. Structural basis of Notch recognition by human gamma-secretase. Nature. 2019;565:192\u2013197. doi: 10.1038/s41586-018-0813-8.", "ArticleIdList": ["10.1038/s41586-018-0813-8", "30598546"]}, {"Citation": "Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., et al. Mutant presenilins of Alzheimer\u2019s disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 1997;3:67\u201372. doi: 10.1038/nm0197-67.", "ArticleIdList": ["10.1038/nm0197-67", "8986743"]}, {"Citation": "Haass C., De Strooper B. The presenilins in Alzheimer\u2019s disease--proteolysis holds the key. Science. 1999;286:916\u2013919. doi: 10.1126/science.286.5441.916.", "ArticleIdList": ["10.1126/science.286.5441.916", "10542139"]}, {"Citation": "Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710\u2013713. doi: 10.1038/383710a0.", "ArticleIdList": ["10.1038/383710a0", "8878479"]}, {"Citation": "Kaether C., Haass C., Steiner H. Assembly, trafficking and function of gamma-secretase. Neurodegener Dis. 2006;3:275\u2013283. doi: 10.1159/000095267.", "ArticleIdList": ["10.1159/000095267", "17047368"]}, {"Citation": "Coric V., van Dyck C.H., Salloway S., Andreasen N., Brody M., Richter R.W., Soininen H., Thein S., Shiovitz T., Pilcher G., et al. Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch. Neurol. 2012;69:1430\u20131440. doi: 10.1001/archneurol.2012.2194.", "ArticleIdList": ["10.1001/archneurol.2012.2194", "22892585"]}, {"Citation": "Kumar D., Ganeshpurkar A., Kumar D., Modi G., Gupta S.K., Singh S.K. Secretase inhibitors for the treatment of Alzheimer\u2019s disease: Long road ahead. Eur. J. Med. Chem. 2018;148:436\u2013452. doi: 10.1016/j.ejmech.2018.02.035.", "ArticleIdList": ["10.1016/j.ejmech.2018.02.035", "29477076"]}, {"Citation": "Mehta D., Jackson R., Paul G., Shi J., Sabbagh M. Why do trials for Alzheimer\u2019s disease drugs keep failing? A discontinued drug perspective for 2010\u20132015. Expert Opin. Investig. Drugs. 2017;26:735\u2013739. doi: 10.1080/13543784.2017.1323868.", "ArticleIdList": ["10.1080/13543784.2017.1323868", "PMC5576861", "28460541"]}, {"Citation": "Ables J.L., Breunig J.J., Eisch A.J., Rakic P. Not(ch) just development: Notch signalling in the adult brain. Nat. Rev. Neurosci. 2011;12:269\u2013283. doi: 10.1038/nrn3024.", "ArticleIdList": ["10.1038/nrn3024", "PMC3159580", "21505516"]}, {"Citation": "Mumm J.S., Kopan R. Notch signaling: from the outside in. Dev. Biol. 2000;228:151\u2013165. doi: 10.1006/dbio.2000.9960.", "ArticleIdList": ["10.1006/dbio.2000.9960", "11112321"]}, {"Citation": "Mitani Y., Yarimizu J., Saita K., Uchino H., Akashiba H., Shitaka Y., Ni K., Matsuoka N. Differential effects between gamma-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J. Neurosci. 2012;32:2037\u20132050. doi: 10.1523/JNEUROSCI.4264-11.2012.", "ArticleIdList": ["10.1523/JNEUROSCI.4264-11.2012", "PMC6621706", "22323718"]}, {"Citation": "Elvang A.B., Volbracht C., Pedersen L.O., Jensen K.G., Karlsson J.J., Larsen S.A., Mork A., Stensbol T.B., Bastlund J.F. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo. J. Neurochem. 2009;110:1377\u20131387. doi: 10.1111/j.1471-4159.2009.06215.x.", "ArticleIdList": ["10.1111/j.1471-4159.2009.06215.x", "19519664"]}, {"Citation": "Barten D.M., Meredith J.E., Jr., Zaczek R., Houston J.G., Albright C.F. Gamma-secretase inhibitors for Alzheimer\u2019s disease: balancing efficacy and toxicity. Drugs R D. 2006;7:87\u201397. doi: 10.2165/00126839-200607020-00003.", "ArticleIdList": ["10.2165/00126839-200607020-00003", "16542055"]}, {"Citation": "Tagami S., Yanagida K., Kodama T.S., Takami M., Mizuta N., Oyama H., Nishitomi K., Chiu Y.W., Okamoto T., Ikeuchi T., et al. Semagacestat Is a Pseudo-Inhibitor of gamma-Secretase. Cell Rep. 2017;21:259\u2013273. doi: 10.1016/j.celrep.2017.09.032.", "ArticleIdList": ["10.1016/j.celrep.2017.09.032", "28978478"]}, {"Citation": "Doody R.S., Raman R., Farlow M., Iwatsubo T., Vellas B., Joffe S., Kieburtz K., He F., Sun X., Thomas R.G., et al. A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N. Engl. J. Med. 2013;369:341\u2013350. doi: 10.1056/NEJMoa1210951.", "ArticleIdList": ["10.1056/NEJMoa1210951", "23883379"]}, {"Citation": "Gillman K.W., Starrett J.E., Jr., Parker M.F., Xie K., Bronson J.J., Marcin L.R., McElhone K.E., Bergstrom C.P., Mate R.A., Williams R., et al. Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable gamma-Secretase Inhibitor. ACS Med. Chem. Lett. 2010;1:120\u2013124. doi: 10.1021/ml1000239.", "ArticleIdList": ["10.1021/ml1000239", "PMC4007960", "24900185"]}, {"Citation": "Albright C.F., Dockens R.C., Meredith J.E., Jr., Olson R.E., Slemmon R., Lentz K.A., Wang J.S., Denton R.R., Pilcher G., Rhyne P.W., et al. Pharmacodynamics of selective inhibition of gamma-secretase by avagacestat. J. Pharmacol. Exp. Ther. 2013;344:686\u2013695. doi: 10.1124/jpet.112.199356.", "ArticleIdList": ["10.1124/jpet.112.199356", "23275065"]}, {"Citation": "Coric V., Salloway S., van Dyck C.H., Dubois B., Andreasen N., Brody M., Curtis C., Soininen H., Thein S., Shiovitz T., et al. Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial. JAMA Neurol. 2015;72:1324\u20131333. doi: 10.1001/jamaneurol.2015.0607.", "ArticleIdList": ["10.1001/jamaneurol.2015.0607", "26414022"]}, {"Citation": "Ran Y., Cruz P.E., Ladd T.B., Fauq A.H., Jung J.I., Matthews J., Felsenstein K.M., Golde T.E. gamma-Secretase processing and effects of gamma-secretase inhibitors and modulators on long Abeta peptides in cells. J. Biol. Chem. 2014;289:3276\u20133287. doi: 10.1074/jbc.M113.512921.", "ArticleIdList": ["10.1074/jbc.M113.512921", "PMC3916530", "24352661"]}, {"Citation": "Graham W.V., Bonito-Oliva A., Sakmar T.P. Update on Alzheimer\u2019s Disease Therapy and Prevention Strategies. Annu. Rev. Med. 2017;68:413\u2013430. doi: 10.1146/annurev-med-042915-103753.", "ArticleIdList": ["10.1146/annurev-med-042915-103753", "28099083"]}, {"Citation": "Golde T.E., Koo E.H., Felsenstein K.M., Osborne B.A., Miele L. gamma-Secretase inhibitors and modulators. Biochim. Biophys. Acta. 2013;1828:2898\u20132907. doi: 10.1016/j.bbamem.2013.06.005.", "ArticleIdList": ["10.1016/j.bbamem.2013.06.005", "PMC3857966", "23791707"]}, {"Citation": "Sanz-Blasco S., Valero R.A., Rodriguez-Crespo I., Villalobos C., Nunez L. Mitochondrial Ca2+ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. PLoS ONE. 2008;3:e2718. doi: 10.1371/journal.pone.0002718.", "ArticleIdList": ["10.1371/journal.pone.0002718", "PMC2447871", "18648507"]}, {"Citation": "Woodling N.S., Colas D., Wang Q., Minhas P., Panchal M., Liang X., Mhatre S.D., Brown H., Ko N., Zagol-Ikapitte I., et al. Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer\u2019s disease model mice. Brain. 2016;139:2063\u20132081. doi: 10.1093/brain/aww117.", "ArticleIdList": ["10.1093/brain/aww117", "PMC4939702", "27190010"]}, {"Citation": "Imbimbo B.P., Giardina G.A. gamma-secretase inhibitors and modulators for the treatment of Alzheimer\u2019s disease: disappointments and hopes. Curr. Top. Med. Chem. 2011;11:1555\u20131570. doi: 10.2174/156802611795860942.", "ArticleIdList": ["10.2174/156802611795860942", "21510832"]}, {"Citation": "Xia W., Wong S.T., Hanlon E., Morin P. gamma-Secretase modulator in Alzheimer\u2019s disease: shifting the end. J. Alzheimers Dis. 2012;31:685\u2013696. doi: 10.3233/JAD-2012-120751.", "ArticleIdList": ["10.3233/JAD-2012-120751", "22710916"]}, {"Citation": "Wong L.R., Ho P.C. Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen: implications for the treatment of Alzheimer\u2019s disease. J. Pharm. Pharmacol. 2018;70:59\u201369. doi: 10.1111/jphp.12836.", "ArticleIdList": ["10.1111/jphp.12836", "29034965"]}, {"Citation": "Mitchell J.A., Akarasereenont P., Thiemermann C., Flower R.J., Vane J.R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA. 1993;90:11693\u201311697. doi: 10.1073/pnas.90.24.11693.", "ArticleIdList": ["10.1073/pnas.90.24.11693", "PMC48050", "8265610"]}, {"Citation": "Wang J., Cheng X., Zhang X., Liu G., Wang Y., Zhou W., Zhang Y. A combination of indomethacin and atorvastatin ameliorates cognitive and pathological deterioration in PrP-hAbetaPPswe/PS1(DeltaE9) transgenic mice. J. Neuroimmunol. 2019;330:108\u2013115. doi: 10.1016/j.jneuroim.2019.03.003.", "ArticleIdList": ["10.1016/j.jneuroim.2019.03.003", "30870684"]}, {"Citation": "De Jong D., Jansen R., Hoefnagels W., Jellesma-Eggenkamp M., Verbeek M., Borm G., Kremer B. No effect of one-year treatment with indomethacin on Alzheimer\u2019s disease progression: A randomized controlled trial. PLoS ONE. 2008;3:e1475. doi: 10.1371/journal.pone.0001475.", "ArticleIdList": ["10.1371/journal.pone.0001475", "PMC2194921", "18213383"]}, {"Citation": "Hahn S., Bruning T., Ness J., Czirr E., Baches S., Gijsen H., Korth C., Pietrzik C.U., Bulic B., Weggen S. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer\u2019s disease attenuate the response of cultured cells to gamma-secretase modulators regardless of their potency and structure. J. Neurochem. 2011;116:385\u2013395. doi: 10.1111/j.1471-4159.2010.07118.x.", "ArticleIdList": ["10.1111/j.1471-4159.2010.07118.x", "21091478"]}, {"Citation": "Borgegard T., Jureus A., Olsson F., Rosqvist S., Sabirsh A., Rotticci D., Paulsen K., Klintenberg R., Yan H., Waldman M., et al. First and second generation gamma-secretase modulators (GSMs) modulate amyloid-beta (Abeta) peptide production through different mechanisms. J. Biol. Chem. 2012;287:11810\u201311819. doi: 10.1074/jbc.M111.305227.", "ArticleIdList": ["10.1074/jbc.M111.305227", "PMC3320929", "22334705"]}, {"Citation": "Wagner S.L., Rynearson K.D., Duddy S.K., Zhang C., Nguyen P.D., Becker A., Vo U., Masliah D., Monte L., Klee J.B., et al. Pharmacological and Toxicological Properties of the Potent Oral gamma-Secretase Modulator BPN-15606. J. Pharmacol. Exp. Ther. 2017;362:31\u201344. doi: 10.1124/jpet.117.240861.", "ArticleIdList": ["10.1124/jpet.117.240861", "PMC5454592", "28416568"]}, {"Citation": "Rogers K., Felsenstein K.M., Hrdlicka L., Tu Z., Albayya F., Lee W., Hopp S., Miller M.J., Spaulding D., Yang Z., et al. Modulation of gamma-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. Mol. Neurodegener. 2012;7:61. doi: 10.1186/1750-1326-7-61.", "ArticleIdList": ["10.1186/1750-1326-7-61", "PMC3573960", "23249765"]}, {"Citation": "Peng H., Talreja T., Xin Z., Cuervo J.H., Kumaravel G., Humora M.J., Xu L., Rohde E., Gan L., Jung M.Y., et al. Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable gamma-Secretase Modulator. ACS Med. Chem. Lett. 2011;2:786\u2013791. doi: 10.1021/ml200175q.", "ArticleIdList": ["10.1021/ml200175q", "PMC4018072", "24900267"]}, {"Citation": "Scannevin R.H., Chollate S., Brennan M.S., Snodgrass-Belt P.A., Peng H., Xu L., Jung M.Y., Bussiere T., Arastu M.F., Talreja T., et al. BIIB042, a novel gamma-secretase modulator, reduces amyloidogenic Abeta isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer\u2019s disease. Neuropharmacology. 2016;103:57\u201368. doi: 10.1016/j.neuropharm.2015.12.006.", "ArticleIdList": ["10.1016/j.neuropharm.2015.12.006", "26690893"]}, {"Citation": "Prikhodko O., Rynearson K.D., Sekhon T., Mante M.M., Nguyen P.D., Rissman R.A., Tanzi R.E., Wagner S.L. The GSM BPN-15606 as a Potential Candidate for Preventative Therapy in Alzheimer\u2019s Disease. J. Alzheimers Dis. 2020 doi: 10.3233/JAD-190442.", "ArticleIdList": ["10.3233/JAD-190442", "31958080"]}, {"Citation": "Endres K., Deller T. Regulation of Alpha-Secretase ADAM10 In vitro and In vivo: Genetic, Epigenetic, and Protein-Based Mechanisms. Front. Mol. Neurosci. 2017;10:56. doi: 10.3389/fnmol.2017.00056.", "ArticleIdList": ["10.3389/fnmol.2017.00056", "PMC5355436", "28367112"]}, {"Citation": "Yan L., Deng Y., Gao J., Liu Y., Li F., Shi J., Gong Q. Icariside II Effectively Reduces Spatial Learning and Memory Impairments in Alzheimer\u2019s Disease Model Mice Targeting Beta-Amyloid Production. Front. Pharmacol. 2017;8:106. doi: 10.3389/fphar.2017.00106.", "ArticleIdList": ["10.3389/fphar.2017.00106", "PMC5340752", "28337142"]}, {"Citation": "Li X., Cui J., Yu Y., Li W., Hou Y., Wang X., Qin D., Zhao C., Yao X., Zhao J., et al. Traditional Chinese Nootropic Medicine Radix Polygalae and Its Active Constituent Onjisaponin B Reduce beta-Amyloid Production and Improve Cognitive Impairments. PLoS ONE. 2016;11:e0151147. doi: 10.1371/journal.pone.0151147.", "ArticleIdList": ["10.1371/journal.pone.0151147", "PMC4782990", "26954017"]}, {"Citation": "Singh J.C., Kakalij R.M., Kshirsagar R.P., Kumar B.H., Komakula S.S., Diwan P.V. Cognitive effects of vanillic acid against streptozotocin-induced neurodegeneration in mice. Pharm. Biol. 2015;53:630\u2013636. doi: 10.3109/13880209.2014.935866.", "ArticleIdList": ["10.3109/13880209.2014.935866", "25472801"]}, {"Citation": "Li X., Sun Y., Wei Y., Zhou L., Liu L., Yin P., Liu Y., Wu S., Li J., Lu C. Onjisaponin B (OB) is Neuroprotective During Cognitive Loss Through Immune-mediated and SIRT1 Pathways. Curr. Neurovasc Res. 2018;15:94\u2013102. doi: 10.2174/1567202615666180528071520.", "ArticleIdList": ["10.2174/1567202615666180528071520", "29804532"]}, {"Citation": "Cai H., Wang Y., He J., Cai T., Wu J., Fang J., Zhang R., Guo Z., Guan L., Zhan Q., et al. Neuroprotective effects of bajijiasu against cognitive impairment induced by amyloid-beta in APP/PS1 mice. Oncotarget. 2017;8:92621\u201392634. doi: 10.18632/oncotarget.21515.", "ArticleIdList": ["10.18632/oncotarget.21515", "PMC5696209", "29190943"]}, {"Citation": "Chen D.L., Zhang P., Lin L., Shuai O., Zhang H.M., Liu S.H., Wang J.Y. Protective effect of Bajijiasu against beta-amyloid-induced neurotoxicity in PC12 cells. Cell Mol. Neurobiol. 2013;33:837\u2013850. doi: 10.1007/s10571-013-9950-7.", "ArticleIdList": ["10.1007/s10571-013-9950-7", "23812758"]}, {"Citation": "Xu T.T., Zhang Y., He J.Y., Luo D., Luo Y., Wang Y.J., Liu W., Wu J., Zhao W., Fang J., et al. Bajijiasu Ameliorates beta-Amyloid-Triggered Endoplasmic Reticulum Stress and Related Pathologies in an Alzheimer\u2019s Disease Model. Cell Physiol. Biochem. 2018;46:107\u2013117. doi: 10.1159/000488414.", "ArticleIdList": ["10.1159/000488414", "29587274"]}, {"Citation": "Mao J., Huang S., Liu S., Feng X.L., Yu M., Liu J., Sun Y.E., Chen G., Yu Y., Zhao J., et al. A herbal medicine for Alzheimer\u2019s disease and its active constituents promote neural progenitor proliferation. Aging Cell. 2015;14:784\u2013796. doi: 10.1111/acel.12356.", "ArticleIdList": ["10.1111/acel.12356", "PMC4568966", "26010330"]}, {"Citation": "Yang C., Li X., Mo Y., Liu S., Zhao L., Ma X., Fang Z., Chen J., Chen Y., Yu X., et al. beta-Asarone Mitigates Amyloidosis and Downregulates RAGE in a Transgenic Mouse Model of Alzheimer\u2019s Disease. Cell Mol. Neurobiol. 2016;36:121\u2013130. doi: 10.1007/s10571-015-0226-2.", "ArticleIdList": ["10.1007/s10571-015-0226-2", "26271288"]}, {"Citation": "Wang Z., Liu Q., Zhang R., Liu S., Xia Z., Hu Y. Catalpol ameliorates beta amyloid-induced degeneration of cholinergic neurons by elevating brain-derived neurotrophic factors. Neuroscience. 2009;163:1363\u20131372. doi: 10.1016/j.neuroscience.2009.07.041.", "ArticleIdList": ["10.1016/j.neuroscience.2009.07.041", "19635525"]}, {"Citation": "Huang J.Z., Wu J., Xiang S., Sheng S., Jiang Y., Yang Z., Hua F. Catalpol preserves neural function and attenuates the pathology of Alzheimer\u2019s disease in mice. Mol. Med. Rep. 2016;13:491\u2013496. doi: 10.3892/mmr.2015.4496.", "ArticleIdList": ["10.3892/mmr.2015.4496", "26531891"]}, {"Citation": "Cheignon C., Tomas M., Bonnefont-Rousselot D., Faller P., Hureau C., Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer\u2019s disease. Redox Biol. 2018;14:450\u2013464. doi: 10.1016/j.redox.2017.10.014.", "ArticleIdList": ["10.1016/j.redox.2017.10.014", "PMC5680523", "29080524"]}, {"Citation": "Draper H.H., Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol. 1990;186:421\u2013431. doi: 10.1016/0076-6879(90)86135-i.", "ArticleIdList": ["10.1016/0076-6879(90)86135-i", "2233309"]}, {"Citation": "Jia S.L., Wu X.L., Li X.X., Dai X.L., Gao Z.L., Lu Z., Zheng Q.S., Sun Y.X. Neuroprotective effects of liquiritin on cognitive deficits induced by soluble amyloid-beta1-42 oligomers injected into the hippocampus. J. Asian Nat. Prod. Res. 2016;18:1186\u20131199. doi: 10.1080/10286020.2016.1201811.", "ArticleIdList": ["10.1080/10286020.2016.1201811", "27589374"]}, {"Citation": "Small D.H., Mok S.S., Bornstein J.C. Alzheimer\u2019s disease and Abeta toxicity: from top to bottom. Nat. Rev. Neurosci. 2001;2:595\u2013598. doi: 10.1038/35086072.", "ArticleIdList": ["10.1038/35086072", "11484003"]}, {"Citation": "Cui Y.M., Ao M.Z., Li W., Yu L.J. Effect of glabridin from Glycyrrhiza glabra on learning and memory in mice. Planta Med. 2008;74:377\u2013380. doi: 10.1055/s-2008-1034319.", "ArticleIdList": ["10.1055/s-2008-1034319", "18484526"]}, {"Citation": "Jin H.J., Li C.G. Tanshinone IIA and Cryptotanshinone Prevent Mitochondrial Dysfunction in Hypoxia-Induced H9c2 Cells: Association to Mitochondrial ROS, Intracellular Nitric Oxide, and Calcium Levels. Evid Based Complement. Alternat. Med. 2013;2013:610694. doi: 10.1155/2013/610694.", "ArticleIdList": ["10.1155/2013/610694", "PMC3603679", "23533503"]}, {"Citation": "Maione F., Piccolo M., De Vita S., Chini M.G., Cristiano C., De Caro C., Lippiello P., Miniaci M.C., Santamaria R., Irace C., et al. Down regulation of pro-inflammatory pathways by tanshinone IIA and cryptotanshinone in a non-genetic mouse model of Alzheimer\u2019s disease. Pharmacol Res. 2018;129:482\u2013490. doi: 10.1016/j.phrs.2017.11.018.", "ArticleIdList": ["10.1016/j.phrs.2017.11.018", "29158049"]}, {"Citation": "Li F., Wu X., Li J., Niu Q. Ginsenoside Rg1 ameliorates hippocampal long-term potentiation and memory in an Alzheimer\u2019s disease model. Mol. Med. Rep. 2016;13:4904\u20134910. doi: 10.3892/mmr.2016.5103.", "ArticleIdList": ["10.3892/mmr.2016.5103", "27082952"]}, {"Citation": "Zhu J., Mu X., Zeng J., Xu C., Liu J., Zhang M., Li C., Chen J., Li T., Wang Y. Ginsenoside Rg1 prevents cognitive impairment and hippocampus senescence in a rat model of D-galactose-induced aging. PLoS ONE. 2014;9:e101291. doi: 10.1371/journal.pone.0101291.", "ArticleIdList": ["10.1371/journal.pone.0101291", "PMC4076296", "24979747"]}, {"Citation": "Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., Landreth G.E. Inflammatory mechanisms in Alzheimer\u2019s disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 2000;20:558\u2013567. doi: 10.1523/JNEUROSCI.20-02-00558.2000.", "ArticleIdList": ["10.1523/JNEUROSCI.20-02-00558.2000", "PMC6772401", "10632585"]}, {"Citation": "Wang X., Wang Y., Hu J.P., Yu S., Li B.K., Cui Y., Ren L., Zhang L.D. Astragaloside IV, a Natural PPARgamma Agonist, Reduces Abeta Production in Alzheimer\u2019s Disease Through Inhibition of BACE1. Mol. Neurobiol. 2017;54:2939\u20132949. doi: 10.1007/s12035-016-9874-6.", "ArticleIdList": ["10.1007/s12035-016-9874-6", "27023226"]}, {"Citation": "Fu R.H., Harn H.J., Liu S.P., Chen C.S., Chang W.L., Chen Y.M., Huang J.E., Li R.J., Tsai S.Y., Hung H.S., et al. n-butylidenephthalide protects against dopaminergic neuron degeneration and alpha-synuclein accumulation in Caenorhabditis elegans models of Parkinson\u2019s disease. PLoS ONE. 2014;9:e85305. doi: 10.1371/journal.pone.0085305.", "ArticleIdList": ["10.1371/journal.pone.0085305", "PMC3885701", "24416384"]}, {"Citation": "Hsueh K.W., Chiou T.W., Chiang S.F., Yamashita T., Abe K., Borlongan C.V., Sanberg P.R., Huang A.Y., Lin S.Z., Harn H.J. Autophagic down-regulation in motor neurons remarkably prolongs the survival of ALS mice. Neuropharmacology. 2016;108:152\u2013160. doi: 10.1016/j.neuropharm.2016.03.035.", "ArticleIdList": ["10.1016/j.neuropharm.2016.03.035", "27059126"]}, {"Citation": "Hasanein P. Glabridin as a major active isoflavan from Glycyrrhiza glabra (licorice) reverses learning and memory deficits in diabetic rats. Acta Physiol. Hung. 2011;98:221\u2013230. doi: 10.1556/APhysiol.98.2011.2.14.", "ArticleIdList": ["10.1556/APhysiol.98.2011.2.14", "21616781"]}, {"Citation": "Bolmont T., Clavaguera F., Meyer-Luehmann M., Herzig M.C., Radde R., Staufenbiel M., Lewis J., Hutton M., Tolnay M., Jucker M. Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am. J. Pathol. 2007;171:2012\u20132020. doi: 10.2353/ajpath.2007.070403.", "ArticleIdList": ["10.2353/ajpath.2007.070403", "PMC2111123", "18055549"]}, {"Citation": "Hurtado D.E., Molina-Porcel L., Iba M., Aboagye A.K., Paul S.M., Trojanowski J.Q., Lee V.M. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am. J. Pathol. 2010;177:1977\u20131988. doi: 10.2353/ajpath.2010.100346.", "ArticleIdList": ["10.2353/ajpath.2010.100346", "PMC2947292", "20802182"]}, {"Citation": "Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487\u20131491. doi: 10.1126/science.1058189.", "ArticleIdList": ["10.1126/science.1058189", "11520987"]}, {"Citation": "Choi S.H., Kim Y.H., Hebisch M., Sliwinski C., Lee S., D\u2019Avanzo C., Chen H., Hooli B., Asselin C., Muffat J., et al. A three-dimensional human neural cell culture model of Alzheimer\u2019s disease. Nature. 2014;515:274\u2013278. doi: 10.1038/nature13800.", "ArticleIdList": ["10.1038/nature13800", "PMC4366007", "25307057"]}, {"Citation": "Sreenivasmurthy S.G., Liu J.Y., Song J.X., Yang C.B., Malampati S., Wang Z.Y., Huang Y.Y., Li M. Neurogenic Traditional Chinese Medicine as a Promising Strategy for the Treatment of Alzheimer\u2019s Disease. Int. J. Mol. Sci. 2017;18:272. doi: 10.3390/ijms18020272.", "ArticleIdList": ["10.3390/ijms18020272", "PMC5343808", "28134846"]}, {"Citation": "Liu S.J., Yang C., Zhang Y., Su R.Y., Chen J.L., Jiao M.M., Chen H.F., Zheng N., Luo S., Chen Y.B., et al. Neuroprotective effect of beta-asarone against Alzheimer\u2019s disease: regulation of synaptic plasticity by increased expression of SYP and GluR1. Drug Des. Devel Ther. 2016;10:1461\u20131469. doi: 10.2147/DDDT.S93559.", "ArticleIdList": ["10.2147/DDDT.S93559", "PMC4841421", "27143853"]}, {"Citation": "Chang C.P., Liu Y.F., Lin H.J., Hsu C.C., Cheng B.C., Liu W.P., Lin M.T., Hsu S.F., Chang L.S., Lin K.C. Beneficial Effect of Astragaloside on Alzheimer\u2019s Disease Condition Using Cultured Primary Cortical Cells Under beta-amyloid Exposure. Mol. Neurobiol. 2016;53:7329\u20137340. doi: 10.1007/s12035-015-9623-2.", "ArticleIdList": ["10.1007/s12035-015-9623-2", "26696494"]}], "ReferenceList": []}], "History": [{"Year": "2019", "Month": "12", "Day": "14"}, {"Year": "2020", "Month": "2", "Day": "13"}, {"Year": "2020", "Month": "2", "Day": "14"}, {"Year": "2020", "Month": "2", "Day": "22", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "2", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "11", "Day": "21", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "2", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["32079110", "PMC7072986", "10.3390/ijms21041327", "ijms21041327"]}}], "PubmedBookArticle": []}